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Running  title : 
Factors associated with first thrombosis in patients with Obs-APS  
Abstract  
Objective  To evaluate subsequent rate of thrombosis among obstetric 
antiphospholipid syndrome (Ob-APS) women in a multicenter database of 
antiphospholipid antibody (aPL)-positive patients; and clinical utility of 
adjusted Global Antiphospholipid Syndrome Score (aGAPSS), a validated tool 
to assess the likelihood of developing new thrombosis, in this group of 
patients. 
Design  Retrospective study. 
Setting  APS Alliance For Clinical Trials & International Networking (APS 
ACTION) Clinical Database And Repository. 
Population  Women with Ob-APS. 
Methods  Comparison of clinical and laboratory characteristics; measurement 
of aGAPSS of Ob-APS women with or without thrombosis after initial 
pregnancy morbidity (PM). 
Main Outcome  Measures  Risk factors for thrombosis, aGAPSS. 
Results  Of 550 patients, 126 had Ob-APS; 74/126 (59%) presented 
thrombosis, and 47 (63%) of them developed thrombosis after initial PM, in a 
mean time of 7.6 ± 8.2 years (4.9/100 patient years). Younger age of Ob-APS, 
additional cardiovascular risk factors, superficial vein thrombosis, heart valve 
disease, and multiple aPL positivity increased the risk of first thrombosis after 
PM. Women with thrombosis after PM had higher aGAPSS compared to 
those with Ob-APS alone ([median 11.5 [4-16] vs 9 [4-13], P = 0.0089]).  
Conclusion  Based on retrospective analysis of our multicenter aPL database, 
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additional thrombosis risk factors, selected clinical manifestations, and high-
risk aPL profile increased risk. Women with subsequent thrombosis after Ob-
APS had higher aGAPSS score at registry entry. We believe that aGAPSS is 
a valid tool to improve risk stratification in aPL-positive women. There was no 
funding for this study. 
 
Funding:   
There was no funding for this study. 
 
Keywords:  
Antiphospholipid antibodies, antiphospholipid syndrome, thrombosis, 
preeclampsia, abortion, fetal death 
 
Tweetable  abstract   
More than 60% of obstetric antiphospholipid syndrome women had 
thrombosis after initial pregnancy morbidity 
 
Manuscript  
Introduction:   
Antiphospholipid syndrome (APS) is a multisystem disease that can 
present with thrombosis and/or obstetric complications in patients with 
persistently positive antiphospholipid antibodies (aPL).1 Based on the 
Updated Sapporo APS classification criteria, obstetric APS (Ob-APS) is 
defined as: one or more unexplained deaths of a morphologically normal fetus 
at or beyond the 10th week of gestation (fetal loss); one or more premature 
births of a morphologically normal neonate before the 34th week of gestation 
due to eclampsia or severe preeclampsia; or three or more unexplained 
consecutive spontaneous abortions before the 10th week of gestation.
While recent studies suggest that women with pure Ob-APS are at 
increased risk for future thrombosis compared to women without APS
1 
2–5, 
identifying the subgroup of these patients who are at higher risk for future 
thrombosis is an unmet clinical need. Concomitant systemic lupus 
erythematosus diagnosis, cardiovascular disease risk factors, or high-risk aPL 
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morbidity.3,6–8
The objectives of this retrospective study were to evaluate the 
subsequent rate of thrombosis among Ob-APS women in a multicenter 
database of aPL-positive patients, and to evaluate the clinical utility of GAPSS 
as a tool to identify women at higher future thrombosis risk after presenting 
with Ob-APS. Our hypotheses are that women presenting with an aPL-related 
pregnancy morbidity are at increased risk for future thrombosis, and GAPSS 
is a useful tool to identify the subgroup of these high-risk patients.  
 In this context, the use of a thrombosis scoring system, such as 
the Global Antiphospholipid Syndrome Score (GAPSS), may help risk stratify 
Ob-APS women for future thrombosis risk by subgroups based on traditional 
cardiovascular risk factors and aPL profile. 
 
Methods:  
The APS ACTION Registry was created to study the natural disease 
course over at least 10 years in persistently aPL-positive patients with/without 
other systemic autoimmune diseases.
APS ACTION Clinical Database and Repository (“Registry”): 
9 Each center had ethics committee 
approval and all patients signed informed consent before enrolling the 
registry. A web-based data capture system is used to store patient 
demographics, aPL-related history, and medications. The inclusion criteria are 
positive aPL based on the Updated Sapporo APS Classification Criteria1 
Data retrieved were age and type of first pregnancy morbidity 
(embryonic loss before 10 weeks of gestation, fetal loss after ten weeks of 
gestation, premature birth, and preeclampsia), age and type of thrombosis 
(arterial or venous), other autoimmune diseases, cardiovascular risk factors 
(hypertension on medication, diabetes on medication, hyperlipidemia on 
medication, obesity [BMI > 30], and smoking) at the time of the registry entry, 
non-criteria manifestations of APS (thrombocytopenia, hemolytic anemia, 
livedo reticularis, aPL, nephropathy, and valve disease); aPL data, and 
at 
least twice, greater than 12 weeks apart, within one year prior to enrollment. 
For the purpose of this retrospective baseline registry analysis, we included 
Ob-APS women with or without thrombosis after the initial diagnosis of 
pregnancy morbidity. The retrospective study follow-up period is from the first 
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medications. There was no funding and patients were not involved in this 
study. 
 
Global Antiphospholipid Syndrome Score is a validated tool to assess 
the likelihood of developing new thrombosis, which was originally developed 
based on lupus patients
Global Antiphospholipid Syndrome Score (GAPSS): 
10 and then validated in primary APS patients.11 
Global Antiphospholipid Syndrome Score includes the following points based 
on a linear transformation derived from the B regression: positive 
anticardiolipin antibody IgG/M  is scored five points;  anti-β2
The primary study outcome was documented thrombosis (venous 
and/or arterial), confirmed by imaging studies.  
 glycoprotein-I 
IgG/M four points; lupus anticoagulant test four points;  anti-
phosphatidylserine/prothrombin antibodies (aPS/PT) IgG/IgM three points; 
hyperlipidemia  three points; and arterial hypertension one point. For the 
purpose of our analysis, we used the adjusted version of GAPSS (aGAPSS), 
which excludes aPS-PT, as this test was not available for most of the registry 
patients. 
 
Although patients included in APS ACTION registry are followed 
prospectively, in this retrospective study we analyzed the baseline clinical and 
laboratory characteristics of aPL-positive women presenting with pregnancy 
morbidity with a comparison between those with and without subsequent 
thromboses. We also calculated the mean cumulative adjusted GAPSS 
(aGAPSS) for each group.
Statistical analysis: 
The univariate analysis was performed using the Pearson, χ2 and 
Fisher exact tests to assess the association between thrombosis and risk 
factors. The demographic, clinical and serologic parameters considered in the 
univariate analysis are listed in Table 1. Multivariate logistic regression 
analysis was performed to identify significant independent factors adjusted for 
the potential confounding risk factors able to predict thrombosis. The final 
multivariate logistic regression model included the following variables: age, 
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aPL profile, type of pregnancy morbidity, and treatment. The forward 
conditional techniques were used to finalize the model. 
 
Results:  
Of 550 patients included in the APS ACTION registry as of May 2015, 
419 (76%) were female. We excluded 131 (31%) women with no pregnancy 
history, and 162 (39%) with history of pregnancy but who did not fulfill the 
Updated APS Classification Criteria for Ob-APS (with/without any morbidity).1
The clinical and laboratory characteristics of Ob-APS women with or 
without thrombosis after pregnancy morbidity are described in Table 1. Fetal 
loss was the most common pregnancy morbidity in both groups (65% and 
64%, respectively). The clinical and laboratory characteristics of women were 
not different except women with thrombosis after Ob-APS, compared to those 
with pure Ob-APS: a) had the first pregnancy morbidity at a younger age (26.2 
± 5.5 vs 28.9 ± 6.7 years, p=0.03); b) more frequently had superficial vein 
thrombosis (6 vs 1, p=0.01) and heart valve disease (6 vs 1, p=0.01); c) more 
frequently had hypertension (21 vs 11, p=0.01), hyperlipidemia (8 vs 3, 
p=0.03), and smoking history (18 vs 9, p=0.009) at study entry; and d) more 
frequently were positive for lupus anticoagulant (alone or with other aPL) (42 
vs 35, p=0.004). The mean age of inclusion in the registry of women with Ob-
APS without thrombosis was 40.8 years (+ 9.8).  
  
Of the remaining 126 (30%) women with Ob-APS, 74 (59%) had a history of 
thrombosis at time of cohort entry (venous: 43; arterial: 22; and both: 9): 47 
(64%) after pregnancy morbidity and 27 (36%) before Ob-APS. For the 
purpose of this study, only women with vascular thrombosis after the initial 
pregnancy morbidity (n = 47) and those with Ob-APS without thrombosis (n = 
52) were included.  
Among Ob-APS women with subsequent thrombosis, the mean time 
between pregnancy morbidity and thrombosis was 7.6 + 8.2 years (4.9 per 
100 patient years) (figure S1). Based on the registry entry data, at least one 
cardiovascular risk factor and multiple aPL positivity (defined as positivity for 
more than one aPL criteria test1) were identified using stepwise multivariate 
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Obstetric-APS women with subsequent thrombosis after pregnancy 
morbidity had higher aGAPSS than those with Ob-APS alone ([median 11.5 
[4-16] vs 9 [4-13], p = 0.0089], data shown as box-and-whisker plot in Figure 
1). Higher aGAPSS were also shown after a subgroup analysis of the type of 
thrombosis (12 [4-16] for arterial thrombosis, 11 [4-13] for venous thrombosis, 
and 9 [4-13] for Ob-APS alone, p = 0.038 and p = 0.044, respectively). 
 
Discussion :  
This is the first multicenter international large scale analysis of Ob-APS 
women for their risk of first thrombosis after the initial pregnancy morbidity. In 
addition, our study is the first attempt to quantify the thrombosis risk of these 
women. In our cohort, we observed that 63% of APS women presenting with 
pregnancy morbidity eventually developed thrombosis after a mean time of 
7.6 years (4.9 per 100 patient years), which was independently associated 
with multiple aPL positivity. We also found that pregnancy morbidity at a 
younger age, concomitant cardiovascular risk factors, and non-criteria 
manifestations (namely superficial vein thrombosis and heart valve disease) 
were predictors of new thrombosis. 
Main Findings 
 
Our study has several strengths and limitations. Although our study is 
one of the largest international analyses of the association between Ob-APS 
and subsequent thrombosis, the study is limited by retrospective, case control 
study design. Similarly the retrospective assessment of cardiovascular 
disease risk factors at the time of the registry entry, but not at the time of 
thrombosis, limits the accuracy of aGAPSS.  
Strengths and Limitations 
 
The increased risk of thrombosis following pregnancy morbidity in aPL-
positive women, compared to general population, has been previously 
described both retrospectively
Interpretation 
2 and prospectively3; although not all studies 
agree4. A 10-year prospective study of 1,592 women with three consecutive 
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or beyond the 10th  week of gestation compared the frequencies of thrombosis 
among women with pregnancy morbidity with positive aPL (n: 517), women 
carrying the coagulation factor polymorphisms F5 6025 or F2 rs1799963 (n: 
279), and women with negative thrombophilia screening results (n: 
796).3 Annual rates of deep vein thrombosis (1.46%; range: 1.15%-1.82%), 
pulmonary embolism (0.43%; range: 0.26%-0.66%), superficial vein 
thrombosis (0.44%; range: 0.28%-0.68%), and cerebrovascular events 
(0.32%; range: 0.18%-0.53%) were significantly higher in women with aPL 
than in the other groups, despite low-dose aspirin. On the other hand, one 
study described a thrombosis rates after fetal loss in women with APS to be of 
1.3 and 7.4 per 100 patient-years in aspirin-treated and untreated women, 
respectively.5 A retrospective cohort of 32 women with Obs-APS treated with 
aspirin reported an overall thrombosis rate of 3.3 per 100 patient-year; 
however, thrombosis rate with double or triple aPL positivity was 4.6 per 
patient-year (n:7 and n:14, respectively), and 10 per 100 patient-years with 
SLE-associated Ob-APS.
The clinical utility of the adjusted GAPSS in assessing the thrombotic 
risk in different clinical scenarios has been previously described and 
validated, as recently summarized in a systematic review.
12 
13 In the first 
description of patients with SLE; it was observed that GAPSS values ≥ 10 had 
the best diagnostic accuracy for APS. In patients with primary APS, GAPSS 
values ≥11 were strongly associated with a higher risk of recurrence [OR 
18.27 (95% CI 3.74, 114.5)], showing the best accuracy in terms of sensitivity 
and specificity.14 More recently, in a cohort of patients with autoimmune 
disease, Fernandez Mosteirin et al. showed that aGAPSS values≥ 5 had the 
best diagnostic accuracy (AUC = 0.661; p< 0.001) for any thrombotic event.15 
Cut-off values may differ in different of cohorts,14,16
Several studies also demonstrated that aGAPSS seems to be a valid 
tool to assess the likelihood of developing new thrombotic events in patients 
with APS and may guide pharmacological treatment for high-risk patients. 
 which suggests that 
baseline characteristics in divergent groups of patients can account for 
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This score has been independently validated in different APS 
populations11,14,17 and also in specific groups, such as young APS patients 
with acute myocardial infarction.
In a recent study, aGAPSS baseline values were statistically higher in 
patients with APS and history of thrombosis compared with those without.
16 
15  A 
Chinese cohort reported a higher aGAPSS in patients with thrombosis than 
those with pregnancy morbidity only, but patients with both thrombosis and 
pregnancy morbidity had no statistical difference in aGAPSS when compared 
to those with Ob-APS only.18 
 
We showed that Ob-APS women who 
experience thrombosis after initial pregnancy morbidity have higher aGAPSS 
values, when compared to those without thrombosis. 
Conclusion  
Our retrospective analysis of a large scale aPL registry suggests that: 
a) among women with both thrombotic and Ob-APS, more than half 
developed thrombosis after an initial aPL-related pregnancy morbidity; and b) 
younger age at the time of onset for Ob-APS related event, additional 
cardiovascular risk factors, superficial vein thrombosis, heart valve disease 
and multiple aPL positivity increased the risk of the first thrombosis after 
pregnancy morbidity. In addition, the aGAPSS may be a valid tool for a 
substantial improvement in risk stratification for thrombosis in women with Ob-
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Table 1. Clinical and Laboratory Characteristics of Women with Obstetric Antiphospholipid 
Syndrome (Obs-APS) in APS ACTION registry with/without Subsequent Non-gravid Thrombosis. 
Variables, n (%) 
Obstetric APS only 
(n=52) 




  Demographics 
Age of first pregnancy morbidity 
 
28.9 + 6.77 
 
26.25 + 5.52 
 
0.03 
Associated Autoimmune Disease 
  No other autoimmune disease 










  Lupus-like disease (3 American College of 
Rheumatology criteria for lupus) 
6 (11.5%) 2 (4.2%) 0.09 









Arterial Thrombosis NA 17 (36.1%) NA 
Venous and Arterial Thrombosis NA 5 (10.6%) NA 
Cardiovascular Risk Factors at registry entry    
  Hypertension on medication 11 (21.1%) 20 (42.5) 0.01 
  Diabetes on medication 1 (1.9%) 3 (6.3%) 0.13 
  Hyperlipidemia on medication 3 (5.7%) 8 (17.0%) 0.03 
  Obesity (BMI > 30) 6 (11.5%) 11 (23.4%) 0.06 
  Smoking (ever) 9 (17.3%) 18  (38.2%) 0.009 
First Pregnancy Morbidity    
  Fetal Loss 34 (65.3%) 30 (63.8%) 0.43 
  Premature Birth < 34 week 14 (26.9%) 12 (25.5%) 0.43 
  > Three (pre)-embryonic loss 4 (7.6%) 5 (10.6%) 0.30 
Non-Criteria Manifestations    
  Superficial Vein Thrombosis 1 (1.9%) 6 (12.7%) 0.01 
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  Livedo 6 (11.5%) 11 (23.4%) 0.06 
  Thrombocytopenia 12 (23.0%) 10 (21.2%) 0.41 
  Hemolytic Anemia 3 (5.7%) 4 (8.5%) 0.29 
  Heart Valve Disease 1 (1.9%) 6 (12.7%) 0.01 
  Skin Ulcer 0 4 (8.5%) NA 
  aPL-Nephropathy 2 (3.8%) 0 NA 
Laboratory parameters    
 Lupus Anticoagulant (alone or with  
other autoantibodies) 
35 (67.3%) 42 (89.3%) 0.004 
















Tables  and Figures  
Figure 1. Global Antiphospholipid Syndrome (APS) Score Based on Obstetric APS 
(OAPS) versus Obstetric and Thrombotic APS (O+T APS).  
Data are shown as box plots, where each box represents the 25th–75th percentiles: lines 
inside the box represent he median. The whiskers represent he 95% CI.  
* Assessed by t-test 
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